CVS' Health Services segment posts $43B in revenues as specialty pharmacy and Caremark deals drive 2025 growth prospects.
CVS surges 53.7% YTD as regulatory relief, strong execution and Medicare Advantage momentum fuel investor confidence.
The P/B ratio helps to identify low-priced stocks with high growth prospects. USNA, CVS, PFE, STNE and PSFE are some such stocks.
Here are four discounted PEG stocks that qualify our screening criteria and could be good picks. These are FLEX, CVS, URBN and EXEL.
CVS posts its first favorable MBR in quarters, but elevated cost trends test its ability to sustain the gains.
CVS unveils a $20B digital strategy to tackle healthcare gaps and reshape consumer health experiences.
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CVS Health reportedly plans to invest $20 billion over the next 10 years to build a “tech-enabled consumer health experience” that will encompass the company, its vertically integrated businesses, and other companies, including competitors, who want to join.
PM, CVS, ET, GSK and NWG, which offer high dividends and carry Zacks buy ranks, are strong picks for stability amid volatile market conditions of 2025.
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Perhaps it's not all too surprising to witness the S&P 500 run into turbulence after two of the best years for stock gains in recent memory.
CVS Health (CVS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.